ArticleBiomedicines2024

Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.

Craig A Erickson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.